20 research outputs found
Association of prostate volume with incidence and aggressiveness of prostate cancer
Shadi Al-Khalil, Christine Ibilibor, James Thomas Cammack, Werner de Riese Department of Urology, Texas Tech University Health Sciences Center, Lubbock, TX, USA Objective: The aim of this study was to investigate the possible correlation between prostate volume and aggressiveness and incidence of prostate cancer (PCa).Patients and methods: A chart review of a cohort of 448 consecutive prostate biopsy-naive men was performed. These men underwent at least a 12-core biopsy at our institution due to increased prostate-specific antigen serum levels (>4 ng/mL) and/or suspicious findings on digital rectal examination during the period between 2008 and 2013. Transrectal ultrasound was used to determine the prostate volume.Results: The positive biopsy rate was 66% for patients with a prostate volume of ≤35 cc and 40% for patients with a prostate volume of ≥65 cc (P<0.001). Of the 110 patients testing positive on biopsy with a volume of ≤35 cc, 10 patients (9.1%) had a Gleason score of ≥8. Of the 27 patients testing positive on biopsy with a volume of ≥65 cc, only 1 patient (3.7%) had a Gleason score of ≥8.Conclusion: These results suggest that there may be an association between prostate volume and the incidence and aggressiveness of PCa. The larger the prostate, the lower the positive biopsy rate for PCa and the lower the Gleason score. Keywords: prostate cancer, prostate-specific antigen, prostate volum
EPR Spectra of Transition-Metal Proteins: the Benefits of Data Deposition in Standard Formats
Is the Use of Biologic Additions Necessary to Optimize Periodontal Regenerative Efforts?
Are The Use of Biologic Additions Necessary to Optimize Periodontal Regenerative Efforts?
Model Studies for Molybdenum Enzymes: Structures, Spectra, Electrochemistry and Reactions of Oxo Mo(VI), (V), and (IV) Complexes
Thigh-length compression stockings and DVT after stroke
Controversy exists as to whether neoadjuvant chemotherapy improves survival in patients with invasive bladder cancer, despite randomised controlled trials of more than 3000 patients. We undertook a systematic review and meta-analysis to assess the effect of such treatment on survival in patients with this disease